Consistent with our imputed findings, IL-27 treatment prior to disease onset in the HLA-B27-transgenic rat spondyloarthritis model inhibited spondyloarthritis development through suppression of IL-17/TNF production by CD4 + T-cells 36. Here, IL17A is linked to spondyloarthropathy.